IGI Logo

Strides Pharma Science is currently trading at Rs. 347.50, up by 13.40 points or 4.01% from its previous closing of Rs. 334.10 on the BSE.

The scrip opened at Rs. 336.65 and has touched a high and low of Rs. 349.25 and Rs. 336.05 respectively. So far 37472 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 946.80 on 23-Apr-2021 and a 52 week low of Rs. 304.50 on 04-Mar-2022.

Last one week high and low of the scrip stood at Rs. 349.25 and Rs. 310.40 respectively. The current market cap of the company is Rs. 3116.62 crore.

The promoters holding in the company stood at 29.60%, while Institutions and Non-Institutions held 40.93% and 29.47% respectively.

Strides Pharma Science has entered into sub-license agreement with Medicines Patent Pool (MPP) to commercialize a generic version of Pfizer’s COVID-19 oral treatment in 95 low and middle-income markets.

Developed by Pfizer, the treatment is a SARS-CoV-2 main protease inhibitor oral antiviral therapy. The drug consists of nirmatrelvir tablets which are co-packaged and co-administered with ritonavir tablets. The product has been authorized as a Covid-19 oral therapy for emergency use in the U.S. and many other countries, both amongst high-risk adults and high-risk pediatric patients.

Branded as Kovidax, Strides’ generic version of the Pfizer oral treatment will be launched in 95 markets as part of the sub-licensing agreement with MPP. The product will be manufactured at Strides’ flagship facility in Bengaluru, and the Company has already secured its Active Pharmaceutical Ingredients (API) supplies through a preferred partnership arrangement.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.